Altimmune Inc
(LTS:0A4C)
$
6.3905
-0.4745 (-6.91%)
Market Cap: 457.67 Mil
Enterprise Value: 276.20 Mil
PE Ratio: 0
PB Ratio: 2.65
GF Score: 51/100 Altimmune Inc (LTS:0A4C) Transcripts
- Q4 2023 Altimmune Inc Earnings Call TranscriptMar 27, 2024$8.7 (-0.26%)Earnings
- Altimmune Inc Conference Call TranscriptDec 01, 2023
- Q3 2023 Altimmune Inc Earnings Call TranscriptNov 07, 2023$2.55 (-4.36%)Earnings
- Altimmune Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) TranscriptOct 25, 2023
- Altimmune Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- Q2 2023 Altimmune Inc Earnings Call TranscriptAug 10, 2023$3.15 (+6.77%)Earnings
- Altimmune Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Altimmune Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Q1 2023 Altimmune Inc Earnings Call TranscriptMay 11, 2023$5.24 (+8.94%)Earnings
- Altimmune Inc Conference Call TranscriptMar 21, 2023
- Q4 2022 Altimmune Inc Earnings Call TranscriptFeb 28, 2023$11.94Earnings
- Altimmune Inc Topline Results of Pemvidutide in Subjects with NAFLD Call TranscriptDec 20, 2022
- Altimmune Inc at Piper Sandler Healthcare Conference TranscriptDec 01, 2022
- Q3 2022 Altimmune Inc Earnings Call TranscriptNov 10, 2022$10Earnings
- Altimmune Inc at H C Wainwright Hepatitis B Virus (HBV) Virtual Conference TranscriptOct 18, 2022
- Altimmune Inc Conference Call TranscriptSep 14, 2022
- Q2 2022 Altimmune Inc Earnings Call TranscriptAug 11, 2022$13.3 (+3.14%)Earnings
- Altimmune Inc at JMP Securities Life Sciences Conference TranscriptJun 16, 2022
- Q1 2022 Altimmune Inc Earnings Call TranscriptMay 12, 2022$3.99 (+0.63%)Earnings
- Q4 2021 Altimmune Inc Earnings Call TranscriptMar 15, 2022$6.03 (-9.66%)Earnings
- Q3 2021 Altimmune Inc Earnings Call TranscriptNov 10, 2021$11.06 (+2.50%)Earnings
- Altimmune Inc at H C Wainwright NASH Investor Conference (Virtual) TranscriptOct 12, 2021
- Altimmune Inc to Host Key Opinion Leader Call on Pemvidutide Phase 1 Clinical Trial Results - Conference Call TranscriptSep 30, 2021
- Altimmune Inc to Discuss the 12-Week Data from Phase 1 Clinical Trial of ALT-801 - Conference Call TranscriptSep 28, 2021
- Q2 2021 Altimmune Inc Earnings Call TranscriptAug 11, 2021$10.63 (+4.22%)Earnings
- Altimmune Inc Positive Interim Data From ALT-801 Phase 1 Trial In Overweight And Obese Volunteers Conference Call TranscriptJun 16, 2021
- Q1 2021 Altimmune Inc Earnings Call TranscriptMay 17, 2021$13Earnings
- Altimmune Inc to Present AdCOVIDâ„¢ intranasal COVID-19 at the World Vaccine Congress TranscriptMay 04, 2021
- Q4 2020 Altimmune Inc Earnings Call TranscriptFeb 25, 2021$18.13 (-8.72%)Earnings
- Q3 2020 Altimmune Inc Earnings Call TranscriptNov 10, 2020$9.54 (-12.24%)Earnings
- Altimmune Inc Annual Shareholders Meeting TranscriptSep 24, 2020
- Q2 2020 Altimmune Inc Earnings Call TranscriptAug 12, 2020Earnings
- Altimmune Inc Acceptance of IND for Covid-19 Therapeutic Testing - Call TranscriptJun 01, 2020
- Q1 2020 Altimmune Inc Earnings Call TranscriptMay 14, 2020Earnings
- Q4 2019 Altimmune Inc Earnings Call TranscriptMar 27, 2020Earnings
- Q2 2019 Altimmune Inc Earnings Call TranscriptAug 14, 2019Earnings
- 1